Background Lead exposure is a risk factor for cardiovascular disease mortality, but the number of deaths in the USA attributable to lead exposure is poorly defined. We aimed to quantify the relative contribution of environmental lead exposure to all-cause mortality, cardiovascular disease mortality, and ischaemic heart disease mortality.
Introduction
Deaths from cardiovascular disease have declined strikingly in the USA over the past 50 years, but this disease is still the leading cause of death. 1 In 2013, cardiovascular disease accounted for more than 800 000 deaths in the USA (about one in every three deaths), with total costs exceeding US$300 billion annually. 1 Cardiovascular disease mortality is usually attributed to tobacco use, hypertension, diabetes, and lack of physical activity. 2 Environmental lead exposure is an established risk factor for hypertension and a possible risk factor for cardiovascular disease mortality, 3, 4 but its contribution to deaths in the USA is poorly defined.
Lead is one of many recognised risk factors for cardiovascular disease. In experimental studies, 3, 4 chronic exposure to lead caused hypertension and enhanced the development of atherosclerosis by inactivating nitric oxide, increasing formation of hydrogen peroxide, inhibiting endothelial repair, impairing angio genesis, and promoting thrombosis. In human beings, higher concen trations of lead in blood have been associated with hypertension, electrocardiographic abnormalities, peripheral arterial disease, left-ventricular hyper trophy, and cardiovascular disease mortality. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The concentration of lead in blood was associated with cardiovascular mortality in most, but not all, prospective cohort studies. [6] [7] [8] [9] [10] [11] [12] [13] Previous studies of cardiovascular disease mortality in lead-exposed populations have been criticised because they did not account for other risk factors associated with cardiovascular disease mortality, such as cadmium. 4, 14 No studies have estimated the number of deaths in the USA attributable to lead exposure using a nationally representative cohort, and it is unclear whether concentrations of lead in blood lower than 5 µg/dL (<0·24 μmol/L), which is the current action level for adults in the USA, are associated with cardiovascular mortality.
The aim of this study was to extend the duration of follow-up of a previously published analysis 7 and quantify the relative contribution of environmental lead exposure to all-cause mortality and cardiovascular disease mortality using data from the Third National Health and Nutrition Examination Survey (NHANES-III), a prospective, represen tative cohort of the US popu l ation enrolled from 1988 to 1994 and followed up to Dec 31, 2011 .
Methods

Study population
NHANES-III is a multistage stratified survey designed to provide a detailed examination of the health and nutritional status of a nationally representative sample of noninstitutionalised individuals in the USA. Consistent with an earlier analysis of this cohort, 7 we included individuals who were aged 20 years or older at baseline. The protocols for NHANES-III were approved by the National Center for Health Statistics of the Centers for Disease Control and Prevention Institutional Review Board. All participants gave informed consent.
Procedures
Baseline data in NHANES-III were gathered between 1988 and 1994, when individuals participated in a household interview and a medical examination, during which they provided blood and urine samples. Demographic information-including sex, age, ethnic origin, household income, education, residence, smoking status, and social support-was obtained during the household interview. Information on body-mass index (BMI), physical activity, blood pressure, diet, alcohol consum ption, medical history, and prescription drug use was obtained during the medical examination.
Amounts of lead in blood, cadmium and creatinine in urine, cotinine and cholesterol in serum, and glycated haemoglobin (HbA 1c ) were measured from blood and urine samples gathered during the medical examination. Laboratory methods for the processing of blood and urine samples are described in detail elsewhere. 15 Quantification of lead in whole blood samples, which entailed extensive quality control, was done using graphite furnace atomic absorption spectrophotometry. 16 The detection limit for lead in blood was 1·0 µg/dL (0·048 μmol/L). For study participants who had concentrations of lead in blood below the level of detection, we imputed an amount of 0·7 µg/dL (0·034 μmol/L), which is the level of detection divided by the square root of 2. 17 A full description of mortality linkage methods is available from the National Center for Health Statistics (NCHS). 18 Briefly, NCHS staff linked participants in NHANES-III to underlying cause of death in the National Death Index with a series of identifiers-eg, social security number and date of birth-using probabilistic matching criteria. Individuals were followed up to Dec 31, 2011 ; if a match was not made with the National Death Index, that person was assumed to be alive as of that date. In a validation study using mortality-linked data from the first NHANES study (NHANES-I; 1971-75), 96% of deceased participants and 99% of those still alive were classified correctly. 19 The underlying cause of death was obtained using codes from the International Classification of Diseases ninth version (ICD-9; 1988-98) or tenth version (ICD-10; 1999 . We identified deaths from all causes, cardiovascular disease (ICD-9 390-459; ICD-10 I00-I99) and ischaemic heart disease (ICD-9 410-414; ICD-10 I20-I25; appendix p 1).
Statistical analysis
We have weighted results (percentiles, means, and point estimates) to account for the complex survey design of NHANES-III, and these data are representative of the US Census civilian non-institutionalised population. We calculated hazard ratios (HRs) for continuous concentrations of lead in blood, using Cox proportional hazards models. Every participant's survival-as defined by the 
Research in context
Evidence before this study We searched PubMed between 1980 and Oct 1, 2017, with terms including "mortality", "blood lead concentration", "cardiovascular mortality", and "population attributable risk". We also searched citations of all identified studies. We restricted our search to English language publications. We included human studies. Many studies have linked concentrations of lead in blood with hypertension and mortality from cardiovascular disease. The number of deaths in the USA attributable to lead exposure has not been estimated using a nationally representative cohort, and it is unclear if concentrations of lead in blood lower than 5 µg/dL (<0·24 μmol/L) are associated with all-cause mortality or cardiovascular disease mortality.
Added value of this study
Our study is, to our knowledge, the first to estimate in a nationally representative sample the contribution of concentrations of lead in blood to the number of deaths from all causes and from cardiovascular disease. Although we cannot exclude residual confounding, we estimate that about 400 000 deaths are attributable to lead exposure every year in the USA, of which 250 000 are from cardiovascular disease. Concentrations of lead in blood lower than 5 µg/dL (<0·24 μmol/L) are an important, but largely ignored, risk factor for death in the USA, particularly from cardiovascular disease.
Implications of all the available evidence
Quantifying the contribution of environmental lead exposure to cardiovascular disease mortality is essential to understand trends in mortality and develop comprehensive strategies to prevent cardiovascular disease.
NHANES-III protocol-was the time between the medical examination and the date of death, the participant's 90th birthday, or Dec 31, 2011, whichever came first. 18 We assessed concentrations of lead in blood both as a continuous variable and categorically with tertiles. We fitted five-knot restricted cubic splines to visualise the shape of the dose-response relation of concentrations of lead in blood for all-cause mortality, cardiovascular disease mortality, and ischaemic heart disease mortality, and to investigate whether the relations should be judged linear or log-linear.
We weighted demographic and environmental variables to approximate distributions in the USA by using the provided sample weights to account for oversampling of young children, older people, black people, and individuals of Mexican-American ethnic origin in the NHANES-III survey. We adjusted for variables recognised widely as potential confounders for cardiovascular disease mortality. [2] [3] [4] [5] [6] [7] [8] [9] [10] We adjusted all primary models for age (continuous and age-squared), sex, household income (<US$20 000 or ≥$20 000 per year), ethnic origin (white, black, Mexican-American), BMI (derived from participants' height and weight measurements and categorised as normal [<25·0 kg/m²], overweight [25·0-29·9 kg/m²], or obese [≥30·0 kg/m²]), smoking status (self-reported [never, current, and former] or amounts of cotinine in serum [≥10 ng/mL]), alcohol consumption (four or fewer drinks per month or more than four drinks per month), physical activity (categorised according to frequency of activity in the previous month [none, 1-14 times, or ≥15 times]), and amount of cadmium in urine (standardised by amount of creatinine in urine and categorised in tertiles). Blood pressure was measured three times during the NHANES-III household interview and three times during the medical examination. We excluded the first reading and used the average of all remaining blood pressure measurements to classify every participant's hypertension status (defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg). The Healthy Eating Index, which was derived from food frequency questionnaires and scored on a scale from 1 to 100, was categorised in tertiles. 20 Finally, we included HbA 1c and amount of cholesterol in serum as continuous measures.
We calculated population attributable fractions for continuous concentrations of lead in blood using previously described methods 21 to estimate the proportional reduction in mortality that would occur if recorded amounts of lead in blood in the entire US population aged 20 years and older were reduced to 1·0 µg/dL (0·048 µmol/L). Absolute numbers of deaths were based on the average annual number of deaths from all causes, cardiovascular disease, and ischaemic heart disease from 1988 to 2011. 22, 23 The standard method for calculating the population attributable fraction is a simple comparison of the relative risk in the exposed population weighted by the proportion exposed with the relative risk in the unexposed population weighted by the proportion unexposed. To utilise individual measures of lead in blood and their associated HR estimates, we calculated the population attributable fraction or population impact factor using the integral of the HR estimates weighted by the log-normal population distribution of measured concentrations of lead in blood over the total range (0·70-56·0 µg/dL [0·034-2·70 μmol/L]) for all-cause mortality, cardiovascular disease mortality, and ischaemic heart disease mortality, as described previously. 19 We calculated CIs for population attributable fractions using a substitution method proposed by Daly. 24 We evaluated the proportional hazards assumption using Schoenfeld residuals; 25 none of the models violated the assumption. Finally, we accommodated the com plex survey design of NHANES-III using SUDAAN (version 10.0.1) to provide weighted national estimates and Taylor linearisation to obtain associated variance estimates. 26 We also did several secondary analyses. To assess the effects of low-level exposure to lead, we restricted our analysis to participants who had amounts of lead in blood lower than 5 µg/dL (<0·24 μmol/L). We tested for confounding of concentrations of lead in blood and hypertension for all-cause mortality and cardiovascular disease mortality by examining the change in the estimates for amounts of lead in blood in models with and without hypertension. We also investigated the change in estimates for hypertension in models with and without concentrations of lead in blood. Next, we assessed whether characterising potential confounders-eg, diabetes, HDL, hypertension, alcohol intake, household incomedifferently than in our primary analyses would alter our results appreciably. We also investigated the effect of secular trends on HRs for concentrations of lead in blood by examining NHANES-III phase 1 (1988-91) and phase 2 (1991-94) data separately. Finally, we assessed effect modification of the relation between concentration of lead in blood and key characteristics (eg, sex, age, urban residence, 27 ethnic origin, smoking status, and diabetes).
Role of the funding source
The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
The sample population included 18 825 adults aged 20 years or older. Of these, 17 030 (90%) had a medical examination and home interview. 1419 (6%) participants were missing a result for either concentration of lead in blood or cadmium in urine, 1314 (7%) were missing other covariates, and eight (0·1%) had insufficient identifiers to link with the National Death Index. Thus, 14 289 (76%) participants were included in this analysis. 1150 (9%) individuals had concentrations of lead in blood below the level of detection and had an amount of 0·7 µg/dL (0·034 μmol/L) imputed. Characteristics of participants who were included in the analysis differed from those with missing data for some characteristics, such as ethnic origin, alcohol intake, and the prevalence of diabetes (appendix p 2).
During median follow-up of 19·3 years (IQR 17·6-21·0), 4422 participants died; 1801 (38%) were attributable to cardiovascular disease and 988 (22%) to ischaemic heart disease. Concentrations of lead in blood, which ranged from 1·0 µg/dL to 56 µg/dL (0·048 μmol/L to 2·70 μmol/L), were right-skewed with a geometric mean at baseline of 2·71 µg/dL (geometric SE 0·131); 3632 (20%) participants had amounts of lead in blood of 5 µg/dL or higher (≥0·24 μmol/L). Participants who had the highest concentrations of lead in blood were older, less educated, and more likely to be male, to smoke cigarettes, to consume larger amounts of alcohol, and to have less healthy diets (table 1). Participants who had high concentrations of lead in blood were also more likely to have elevated amounts of cholesterol in serum and higher rates of hypertension and diabetes.
Analysis of restricted cubic splines indicated that adjusted HRs were steeper at lower concentrations of lead in blood than at higher concentrations (figure 1). A model was fitted using the log 10 of measurements of lead in blood in the proportional hazards model and adjusted HRs and 95% CIs were calculated for all-cause mortality, cardiovascular disease mortality, and ischaemic heart disease mortality, as well as for other characteristics ( figure 2 ). An increase in the concentration of lead in blood from 1·0 µg/dL to 6·7 µg/dL (0·048 μmol/L to 0·324 μmol/L), which represents the tenth to 90th percentiles, was associated significantly with all-cause mortality (HR 1·37, 95% CI 1·17-1·60), cardiovascular disease mort ality (1·70, 1·30-2·22), and ischaemic heart disease mortality (2·08, 1·52-2·85; table 2). Population attributable fractions were calculated to show the proportional reduction in all-cause mortality, cardiovascular disease mortality, and ischaemic heart disease mortality that would occur if recorded concentrations of lead in blood were reduced to 1·0 µg/dL or lower (≤0·048 μmol/L). The adjusted popu la tion attributable fraction for all-cause mortality was 18% (95% CI 10·9-26·1), equivalent to 412 000 (95% CI 250 000-598 000) deaths each year (table 2). Adjusted population attributable fractions were 28·7% (95% CI 15·5-39·5) for cardiovascular disease mortality and 37·4% (23·4-48·6) for ischaemic heart disease mortality, equivalent to 256 000 cardiovascular disease deaths and 185 000 ischaemic heart disease deaths annually ( figure 3) . In analyses restricted to participants who had concentrations of lead in blood lower than 5 µg/dL (<0·24 μmol/L), an increase in lead in blood from 1·0 µg/dL to 5·0 µg/dL (0·048 μmol/L to 0·242 μmol/L), which represents the tenth to 80th percentiles, was associated significantly with all-cause mortality (HR 1·38, 95% CI 1·15-1·66), cardiovascular disease mortality (1·95, 1·46-2·60), and ischaemic heart disease mortality (2·57, 1·56-4·52).
In secondary analyses, no appreciable attenuation or confounding of estimates for concentration of lead in blood or hypertension was noted when these variables were included or excluded consecutively in our primary model. The results of our primary analysis did not change substantially when we made several adjustments: characterised diabetes as a categorical instead of a continuous measure; adjusted for both HDL and cholesterol; adjusted for hypertension status (ie, systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg and use of anti-hypertension drugs); adjusted for household income using the poverty index ratio (instead of <$20 000 or ≥$20 000 per year); characterised hypertension as a continuous measure of both systolic blood pressure and diastolic blood pressure instead of a categorical measure; characterised alcohol intake as one or no drink per day versus more than one drink per day (instead of four or fewer drinks versus more than four drinks per month); or excluded participants who had a concentration of lead in blood lower than 1·0 µg/dL (0·048 µmol/L; appendix pp 3, 4). Median concentrations of lead in blood decreased by 22% from NHANES-III phase 1 (1988-91) to phase 2 (1991-94). Consistent with the steeper increase in relative risk, at lower concentrations of lead in blood, the rate of increase in relative risk was steeper for participants who were studied during NHANES-III phase 2 (1991-94) than phase 1 (1988-91; appendix p 4). Examination of effect modification of the relation between concentration of lead in blood and key characteristics showed that HRs for participants younger than 50 years were significantly larger than were those for participants aged 50 years or older, for all-cause mortality (HR 2·24, 95% CI 1·50-3·34 vs 1·53, 1·18-1·98; p=0·003 for interaction), cardiovascular disease mortality (2·93, 1·60-5·36 vs 2·08, 1·35-3·19; p=0·01), and ischaemic heart disease mortality (4·68, 2·42-9·05 vs 2·46, 1·51-4·01; p=0·02). The HR for cardiovascular disease mortality was significantly larger for non-smokers than smokers (HR 2·19, 95% CI 1·47-3·26 vs 1·32, 0·86-2·05; p=0·03 for interaction).
Discussion
Our findings suggest that, of 2·3 million deaths every year in the USA, about 400 000 are attributable to lead exposure, an estimate that is about ten times larger than the current one. 28 The key reason for this difference is because the previous estimate assumed cardiovascular disease was only evident at concentrations of lead in blood as low as 5 μg/dL. 28 Our findings show that concentrations of lead in blood lower than 5 μg/dL (<0·24 μmol/L) are associated with all-cause mortality, cardiovascular disease mortality, and ischaemic heart disease mortality. In other studies, amounts of lead in blood lower than 10 μg/dL (<0·483 μmol/L) were associated with cardiovascular disease mortality, 7, 9, 10 but our study is the first to test whether the relation with cardiovascular disease mortality was evident in a population with concentrations of lead in blood below 5 μg/dL (<0·24 μmol/L). These results suggest that lowlevel lead exposure is an important, largely overlooked, risk factor for death in the USA, particularly for cardiovascular disease deaths.
Our results accord with those of other populationbased studies showing that concentrations of lead in either blood or bone are risk factors for all-cause mortality and cardiovascular disease mortality. [5] [6] [7] [8] [9] [10] [11] [12] [13] A significant association was noted between increased lead exposure and all-cause mortality in six prospective studies, 6, 7, 9, [11] [12] [13] 29 and a significant association was reported between increased lead exposure and cardiovascular mortality in five of six prospective studies. 6, 7, 9, [11] [12] [13] No association between concen tration of lead in blood and cardiovascular disease mortality was noted after adjustment for other risk factors in a study 29 that only included 19 deaths from cardiovascular disease.
In our study, the estimated number of deaths from all causes and cardiovascular disease that were attributable to concentrations of lead in blood were surprisingly large; indeed, they were comparable with the number of deaths from current tobacco smoke exposure. The HR for all-cause mortality from tobacco exposure was larger than that for concentration of lead in blood, but only 20% of the US population smoked tobacco. By contrast, 90% of participants were exposed to lead; a smaller relative risk for a prevalent exposure can result in a larger population attributable fraction. Concentrations of lead in blood lower than 5 μg/dL (<0·24 μmol/L) were associated with an increased risk of cardiovascular disease mortality. This result contrasts with conclusions of the National Toxicology Report, 5 which noted that evidence was limited for an association between amounts of lead in blood less than 10 μg/dL and increased cardiovascular-related mortality. We also reported that risk coefficients for cardiovascular disease in the subset of participants with concentrations of lead in blood lower than 5 μg/dL (<0·24 μmol/L) were generally larger than coefficients in the total sample. Although the rate of increase in mortality was greatest with low amounts of lead in blood, HRs indicate that the risk of cardiovascular disease mortality is rising with higher amounts of lead in blood, but at a diminished rate. These results, which accord with those of an earlier study in this same cohort but of shorter duration, 7 should not be surprising; despite the striking reductions in concentrations of lead in blood over the past 50 years, amounts found nowadays in adults are still ten times to 100 times higher than people living in the preindustrial era (ie, 700-1000 years ago). 30 Moreover, the assumption that there are thresholds for specific toxicants-eg, lead, tobacco, and airborne particles-is slowly eroding. 31 The cardiovascular toxicity of lead stems from various mechanisms. In experimental studies, lead causes hypertension, results in oxidative stress and inflammation, diminishes endothelium relaxation, and promotes development of atherosclerosis and thrombosis. 3, 4 In human beings, lead is a recognised risk factor for hypertension and has been associated with peripheral arterial disease, electrocardiographic abnormalities, and left-ventricular hypertrophy. 4, 10 In a randomised controlled trial of patients who had had a myocardial infarction, chelation with EDTA and multivitamin therapy led to an 18% reduction in cardiovascular events; patients with diabetes in the trial had a 34% reduction in cardiovascular events. 32 Collectively, these findings suggest, but do not prove, that atherosclerosis and hypertension both could serve as underlying mechanisms for the cardiovascular toxicity of lead.
Our study has limitations. The key limitation is that we relied on baseline measures of exposure to predict death over the subsequent two decades. Some measures (eg, concentration of lead in blood) might be more stable than other risk factors (eg, diet). Lead that is circulating in whole blood of adults is an indicator of both past and ongoing exposures. Serial measures of concentrations of lead in blood or bone, which are better indicators of cumulative exposure than one concentration of lead in blood, 9 would have strengthened this study; indeed, our reliance on one measurement for concentration of lead in blood might underestimate the contribution of lead exposure to mortality. Moreover, we relied on death certificates for the underlying cause of death, but they are imperfect. We adjusted for co-exposure to cadmium, but we were not able to adjust for air pollutants or arsenic, both of which are risk factors for cardiovascular disease mortality. 33 Finally, and perhaps most importantly, although we adjusted for an extensive array of potential confounders, we cannot exclude residual confounding that might result in an overestimation of the effect of concentrations of lead in blood, particularly from socioeconomic and occupational factors that were either not measured or measured inadequately. Yet, the shape of the dose-response argues against confounding to account for our results because the confounders, which are correlated positively with amounts of lead in blood, are found primarily in the highest risk groups (table 1) ; the steepest increase in risk occurs at the lower concentrations of lead in blood.
In conclusion, our study findings suggest that low-level environmental lead exposure is an important risk factor for death in the USA, particularly from cardiovascular disease. It is not surprising that lead exposure is overlooked; it is ubiquitous, but insidious and largely beyond the control of patients and clinicians. Although reducing the amount of lead in blood might cut a patient's risk of cardiovascular disease mortality, 32 it is more accurate to view this study as estimating how many deaths might have been prevented if historical exposures to lead had not occurred. Indeed, this study suggests that estimating the contribution of environmental lead exposure is essential to understand trends in cardiovascular disease mortality and develop comprehensive strategies to prevent cardiovascular disease. 34, 35 
